Repligen Co. (NASDAQ:RGEN) Shares Acquired by Watershed Asset Management L.L.C.

Watershed Asset Management L.L.C. increased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 27.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,900 shares of the biotechnology company’s stock after acquiring an additional 1,900 shares during the period. Repligen makes up approximately 1.9% of Watershed Asset Management L.L.C.’s portfolio, making the stock its 11th biggest holding. Watershed Asset Management L.L.C.’s holdings in Repligen were worth $1,600,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of RGEN. DekaBank Deutsche Girozentrale lifted its position in shares of Repligen by 1.5% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock valued at $1,663,000 after acquiring an additional 159 shares during the period. International Assets Investment Management LLC boosted its position in Repligen by 18,449.1% during the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock worth $10,539,000 after purchasing an additional 58,299 shares in the last quarter. American Century Companies Inc. grew its holdings in Repligen by 97.5% in the third quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after purchasing an additional 107,570 shares during the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Repligen in the fourth quarter valued at $2,625,000. Finally, Atria Investments Inc acquired a new position in shares of Repligen during the 3rd quarter worth $1,046,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on RGEN. KeyCorp raised their target price on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Stifel Nicolaus raised their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and an average price target of $196.70.

Repligen Trading Up 8.8 %

Shares of NASDAQ:RGEN traded up $13.80 during trading on Tuesday, reaching $171.28. The stock had a trading volume of 928,604 shares, compared to its average volume of 538,659. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. The stock has a market cap of $9.56 billion, a P/E ratio of 237.89, a PEG ratio of 5.15 and a beta of 1.02. The business has a fifty day moving average price of $186.62 and a 200-day moving average price of $173.56. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The company had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. During the same period in the previous year, the firm posted $0.68 EPS. Repligen’s revenue was down 16.6% on a year-over-year basis. As a group, analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the sale, the chief operating officer now directly owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, COO James Bylund sold 4,373 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,597 shares of company stock worth $5,039,532. 1.20% of the stock is currently owned by insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.